Cingulate CINGW
NASDAQ CINGW
$0.01 +0.00 (+4.29%)
As of: Sep 9, 2026 · 11:16 AM EDT

Cingulate (CINGW) Cash from Financing Activities (2021 - 2025)

Cingulate's (CINGW) quarterly Cash from Financing Activities came in at $8.6 million in Q4 2025, up 33.17% on a YoY basis from $6.4 million in Q4 2024, and up 487.07% quarter-over-quarter from $1.5 million in Q3 2025.

Analysis

Cingulate (CINGW) Cash from Financing Activities (2021 - 2025) Analysis & Trends

Cingulate (CINGW) has reported Cash from Financing Activities for 5 consecutive years, with $8.6 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 33.17% year-over-year to $8.6 million; the trailing twelve-month figure through Dec 2025 stood at $16.1 million (down 47.6% YoY), and the FY2025 full-year result was $16.1 million, down 47.6% from the prior year.
  • Cash from Financing Activities climbed to $8.6 million in Q4 2025 per CINGW's latest filing, from $1.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $19.9 million in Q4 2021 and bottomed at -$89780.0 in Q4 2022.
  • Historically, Cash from Financing Activities has averaged $4.4 million across 5 years, with a median of $2.6 million in 2023.
  • The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 100.45% in 2022, then soared 252377.63% in 2024.
  • Over 5 years, Cash from Financing Activities stood at $19.9 million in 2021, then slumped by 100.45% to -$89780.0 in 2022, then soared by 1008.26% to $815434.0 in 2023, then jumped by 690.89% to $6.4 million in 2024, then jumped by 33.17% to $8.6 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered $8.6 million, $1.5 million, and $4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Johnson & Johnson 646.24 Bn 625.48 Bn 17.26 Bn -8.78 Bn
2 AbbVie 441.52 Bn 434.96 Bn 12.70 Bn -5.05 Bn
3 Merck 365.75 Bn 358.60 Bn 12.21 Bn 1.76 Bn
4 Novartis Ag 266.61 Bn 258.92 Bn 11.24 Bn -2.02 Bn
5 Pfizer 159.09 Bn 147.39 Bn 10.94 Bn -3.66 Bn
6 Sanofi 52.43 Bn 45.05 Bn 10.79 Bn -2.10 Bn
7 Revolution Medicines 44.04 Bn 44.04 Bn - 2.42 Bn
8 Incyte 25.32 Bn 20.79 Bn 1.57 Bn 65.46 Mn
9 United Therapeutics 21.43 Bn 18.77 Bn 683.80 Mn 122.40 Mn
10 Cingulate 100,214.03 100,214.03 - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 8.59 Mn
Sep 30, 2025 1.46 Mn
Jun 30, 2025 4.18 Mn
Mar 31, 2025 1.92 Mn
Dec 31, 2024 6.45 Mn
Sep 30, 2024 13.40 Mn
Jun 30, 2024 1.08 Mn
Mar 31, 2024 9.89 Mn
Dec 31, 2023 815,434.00
Sep 30, 2023 5.93 Mn
Jun 30, 2023 3.21 Mn
Mar 31, 2023 -3,920.00
Dec 31, 2022 -89,780.00
Sep 30, 2022 5.00 Mn
Jun 30, 2022 -3,745.00
Mar 31, 2022 -3,682.00
Dec 31, 2021 19.91 Mn
Sep 30, 2021 3.47 Mn
Jun 30, 2021 1.81 Mn
Mar 31, 2021 1.35 Mn